Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3159-3168
DOI: 10.1021/acsinfecdis.6c00339 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 24.08.2026. Verfasst von Brett N Cain und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-champaign, Urbana, Illinois61801, United St…. Hauptthemen laut MEDLINE: Triclosan, Anti-Bacterial Agents, Enoyl-(Acyl-Carrier-Protein) Reductase (NADH), Drug Resistance, Bacterial. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Illinois at Urbana-Champaign, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
In an effort to develop efficacious antibacterials that engage targets for which there is no preexisting resistance, inhibition of the enoyl-acyl carrier protein reductase FabI has shown promise, with triclosan and fabimycin as representative members of the two major drug classes that show activity against important bacterial pathogens. Here, we use a morbidostat and whole-genome sequencing approach to comprehensively evaluate the resistance profiles that arise in pathogenic bacteria in response to these FabI inhibitors. When assessed against E. coli, fabimycin and triclosan were found to induce primarily nonoverlapping resistance profiles, leading to minimal cross-resistance between the two compounds. Furthermore, in vivo evaluation of the prominent resistant mutants indicates poor fitness, with the fittest mutant still susceptible to fabimycin. Collectively, these results suggest the combination use of two antibiotics that engage different positions on the same target as a means to kill pathogenic bacteria and limit resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-champaign, Urbana, Illinois61801, United States.
- Sanford Burnham Prebys Medical Discovery Institute , La Jolla, California920376, United States.
- Walter Reed Army Institute of Research , Silver Spring, Maryland20910, United States.
- Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois61801, United States.
ORCID-Profile: Gee W Lau, Andrei L Osterman
Förderung
- University of Illinois at Urbana-Champaign
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Cain, B. N., Kent, J. E., Elane, M., Williams, J. D., Lee, M. R., Lau, G. W., Hergenrother, P. J., & Osterman, A. L. (2026). Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens. ACS Infectious Diseases, 12(9), 3159-3168. https://doi.org/10.1021/acsinfecdis.6c00339
Vancouver
Cain BN, Kent JE, Elane M, Williams JD, Lee MR, Lau GW, et al. Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens. ACS Infectious Diseases. 2026;12(9):3159-3168. doi:10.1021/acsinfecdis.6c00339
BibTeX
@article{Cain2026,
author = {Cain, Brett N and Kent, James E and Elane, Marinela and Williams, John D and Lee, Myung Ryul and Lau, Gee W and Hergenrother, Paul J and Osterman, Andrei L},
title = {Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3159--3168},
doi = {10.1021/acsinfecdis.6c00339}
}
EUVIMED